Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Harmony Biosciences Holdings, Inc. HRMY
$35.92
-$0.39 (-1.07%)
На 18:03, 12 мая 2023
+69.82%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
2198599200.00000000
-
week52high
62.09
-
week52low
29.81
-
Revenue
437855000
-
P/E TTM
11305
-
Beta
0.45202500
-
EPS
3.26000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 12:30
Описание компании
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | Buy | 04 авг 2022 г. |
| Raymond James | Outperform | Outperform | 03 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 03 авг 2022 г. |
| Jefferies | Hold | Buy | 03 авг 2022 г. |
| Goldman Sachs | Neutral | Buy | 13 июл 2022 г. |
| Goldman Sachs | Neutral | Neutral | 21 окт 2022 г. |
| Jefferies | Buy | Hold | 14 окт 2022 г. |
| Raymond James | Outperform | Outperform | 03 ноя 2022 г. |
| Needham | Buy | Buy | 02 ноя 2022 г. |
| Mizuho | Buy | Buy | 08 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Nielsen Jack | D | 2571024 | 2834 | 14 дек 2022 г. |
| Wicki Andreas | D | 2147943 | 130 | 14 дек 2022 г. |
| Wicki Andreas | D | 2148073 | 6320 | 13 дек 2022 г. |
| Wicki Andreas | D | 2154393 | 22391 | 12 дек 2022 г. |
| Nielsen Jack | D | 2573858 | 9847 | 09 дек 2022 г. |
| Nielsen Jack | D | 2583705 | 36878 | 08 дек 2022 г. |
| Nielsen Jack | D | 2620583 | 64026 | 07 дек 2022 г. |
| Wicki Andreas | D | 2176784 | 77853 | 05 дек 2022 г. |
| Serafin Andrew | D | 83729 | 38000 | 02 дек 2022 г. |
| Serafin Andrew | D | 0 | 920 | 02 дек 2022 г. |
Новостная лента
2 Biotechs Making Waves With A Single Product in their Pipeline
MarketBeat
12 янв 2023 г. в 10:10
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?
Zacks Investment Research
11 янв 2023 г. в 09:02
Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IPO Stock Leaders Harmony, ProFrac Outperform Despite Tough 2022 Market
Investors Business Daily
30 дек 2022 г. в 12:52
Despite a struggling IPO market in 2022, Harmony Biosciences and ProFrac are holding up well in the ongoing stock market correction. The post IPO Stock Leaders Harmony, ProFrac Outperform Despite Tough 2022 Market appeared first on Investor's Business Daily.
HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PRNewsWire
22 дек 2022 г. в 08:05
PLYMOUTH MEETING, Pa. , Dec. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that President and CEO, John C.
Harmony Biosciences: Up 40% Since My Last Coverage, Waiting For Another Opportunity
Seeking Alpha
14 дек 2022 г. в 03:42
Harmony has done very well in the few months since I last covered it. I was overly cautious then and did not buy what I see could have been a great investment.